{
"title": "Psilocybin clinical trial data for substance use disorders",
"papers": [
{
"n": 17,
"doi": "10.1001/jamanetworkopen.2026.0972",
"value": "significantly increased long-term abstinence vs nicotine patch",
"cite_key": "Johnson2026",
"condition": "Psilocybin vs nicotine patch for smoking cessation",
"scope_region": "systemic/serotonergic",
"scope_population": "treatment-seeking smokers",
"value_source_sentence": "significantly increased long-term abstinence compared with nicotine patch"
},
{
"n": null,
"doi": "10.1176/appi.ajp.20230887",
"value": "multidimensional personality changes following psilocybin therapy",
"cite_key": "Pagni2025",
"condition": "Psilocybin for AUD - personality assessment",
"scope_region": "central serotonergic",
"scope_population": "AUD patients",
"value_source_sentence": "Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder"
},
{
"n": 1068,
"doi": "10.1016/j.pnpbp.2025.111541",
"value": "adverse event profile manageable in controlled settings",
"cite_key": "Bukovsky2025",
"condition": "Psilocybin safety across clinical trials",
"scope_region": "systemic",
"scope_population": "clinical trial participants",
"value_source_sentence": "safety profile and the management of potential adverse events across 1068 participants"
}
],
"figure_id": "fig_sec11_psilocybin_trials",
"comparison": "Psilocybin trial outcomes for alcohol and tobacco cessation",
"figure_type": "study_summary_table",
"n_definition": "Participants enrolled and completing study protocols",
"source_cluster": 10,
"taxonomic_level": "N/A",
"homogeneity_check": "Studies represent different phases of psilocybin research (pilot vs. safety aggregation). Small sample sizes in efficacy trials (n=17) compared to safety data (n=1068). Blinding adequacy varies. Different target conditions (tobacco vs alcohol) limit direct comparison."
}